Pharma Holdings AS
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus (NCT05889351) | Pharma Holdings AS | 2022-09-19 |
| Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection. (NCT04854928) | Pharma Holdings AS | 2021-05-03 |
| LTX-109 as Treatment for Hidradenitis Suppurativa (NCT04756336) | Pharma Holdings AS | 2021-03-05 |
| A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus (NCT04767321) | Pharma Holdings AS | 2021-02-22 |
Track Pharma Holdings AS automatically
Every clearance here is in the API, with alerts when new ones post.